Aldevron Breakthrough Blog
Webinar On Demand: Cas9-CLIPT Technology
April 30, 2025 by Aldevron
Revolutionizing cell therapy
Are you ready to revolutionize your understanding of cell therapy? Cleaved, LInearized with Protein Template (Cas9-CLIPT) technology is doing just that for many people. Designed to enhance genome editing efficiency by using a dsDNA Nanoplasmid™ vector, this groundbreaking technology involves using a circular plasmid with a single target sequence for the Cas9 ribonucleoprotein (RNP).
In this on-demand webinar, Dr. Krishanu Saha from the University of Wisconsin-Madison discusses “Nonviral CRISPR-based knock-in of chimeric antigen receptor transgenes into T cells for cell therapy.”
Dr. Saha shows how, during the manufacturing process, the Cas9-RNP binds and cleaves the Nanoplasmid, linearizing the double-stranded DNA (dsDNA) in vitro. This linearized template, bound to Cas9-RNP, is then delivered to cells to promote precise knock-in via homology-directed repair. Topics covered during this event include:
- Cas9-CLIPT: Mechanism and Benefits
- Enhancing CAR T Cell Production with Precise Knock-In Techniques
- Overcoming Innate Immune Responses to Foreign Nucleic Acids
- Achieving High Efficiency and Clinically Relevant Yields
- Genomic Analysis, including Transgene Insertion Analysis and Off-Target Analysis
Max Sellman, Gene Editing Product Manager at Aldevron, joins Dr. Saha as they discuss the practical applications of Cas9-CLIPT in CAR T cell manufacturing, providing insights into cutting-edge genome editing technologies and the strategies that can improve nonviral manufacturing processes. Additionally, at the conclusion of the presentation, Saha and Sellman answer questions from the audience during the live event.
Krishanu Saha, PhD, is a Professor and the Retina Research Foundation Kathryn and Latimer Murfee Chair at the University of Wisconsin-Madison. He leads pioneering research in nonviral genome editing methods for stem cells and somatic cells. Dr. Saha is also involved in large-scale collaborative projects, including the NSF Center for Cell Manufacturing Technologies and the NIH Somatic Cell Genome Editing Consortium. His work spans engineering, medicine, and ethics, contributing significantly to the field of therapeutic genome editing.
- Have questions on this topic? Contact Us
- Visit our CRISPR nucleases page
- Learn more about our Nanoplasmid Vector System
- Have an idea for a topic? Let us know!
Aldevron serves the biotechnology industry with custom production of nucleic acids and proteins. Thousands of clients use Aldevron-produced plasmids, RNA and gene editing enzymes for projects ranging from research grade to clinical trials to commercial applications. Aldevron specializes in cGMP manufacturing and is known for inventing the GMP-Source® quality system. Aldevron operates the largest cGMP plasmid DNA manufacturing facility in the world at company headquarters in Fargo, North Dakota, with additional facilities in Madison, Wisconsin.